COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection.

Using patients treated with any non-anti-IL6 biotherapy as the control group, we also found a significant difference in COVID-19 severity in favour of anti-IL6 treated patients (aOR for moderate vs mild, 0.35 [95% CI, 0.15 to 0.83], p ≤ 0.05), although the difference did not reach statistical significance for severe versus mild COVID-19 disease (aOR, 0.40 [95% CI, 0.14 to 1.15]).

also in 111,027 other papers